Abstract: 【Objective】 An experiment was carried out to investigate whether co-administration intranasally of the FMDV DNA vaccine, pcD-VP1 and a construct expressing IL-10 as the molecular adjuvant can enhance mucosal immune responses in murine model. 【Method】 proVAX-IL-10 recombinant plasmid was constructed for eukarytic expression, then the mice were randomly divided into 5 groups and they were immunized i.n. with pcD-VP1 alone or co-immunized with the provax-IL-10 molecular adjuvant on days 0, 14 and 28. After immunization, mucosal sIgA ,T cell proliferation and the expession of cytokines were deteced by ELISA, CFSE staining and intracellular cytokine staining method, respectively. 【Result】 Compared to the group intranasally immunized with pcD-VP1 alone, the group immunized with the molecular adjuvant was induced higher level of mucosal sIgA, and intranasal delivery of the IL-10 con struct with pcD-VP1 significantly enhanced the higher level of antigen specific T cell proliferation and higher expession IL-4 in CD4+ cells inform mucosal site compared to the pcD-VP1 alone. 【Conclusion】 The results demonstrated that intranasal delivery of IL-10 as a mucosal adjuvant can enhance the antigen specific mucosal immune responses in a murine model, which may provide a protection against the FMDV initial infection.

Key words: foot and mouth disease virus, DNA vaccine, interleukin-10, mucosal response